- Home
- SXTP vs GLMD Comparison
SXTP vs GLMD Comparison
Compare SXTP & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- GLMD
- Stock Information
- Founded
- SXTP 2010
- GLMD 2000
- Country
- SXTP United States
- GLMD Israel
- Employees
- SXTP N/A
- GLMD N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- GLMD Health Care
- Exchange
- SXTP Nasdaq
- GLMD Nasdaq
- Market Cap
- SXTP 2.7M
- GLMD 3.0M
- IPO Year
- SXTP 2023
- GLMD 2014
- Fundamental
- Price
- SXTP $2.95
- GLMD $1.57
- Analyst Decision
- SXTP Hold
- GLMD Hold
- Analyst Count
- SXTP 1
- GLMD 1
- Target Price
- SXTP N/A
- GLMD N/A
- AVG Volume (30 Days)
- SXTP 4.8M
- GLMD 105.5K
- Earning Date
- SXTP 05-14-2025
- GLMD 05-29-2025
- Dividend Yield
- SXTP N/A
- GLMD N/A
- EPS Growth
- SXTP N/A
- GLMD N/A
- EPS
- SXTP N/A
- GLMD N/A
- Revenue
- SXTP $681,345.00
- GLMD N/A
- Revenue This Year
- SXTP $95.50
- GLMD N/A
- Revenue Next Year
- SXTP $80.78
- GLMD N/A
- P/E Ratio
- SXTP N/A
- GLMD N/A
- Revenue Growth
- SXTP 168.70
- GLMD N/A
- 52 Week Low
- SXTP $1.41
- GLMD $1.21
- 52 Week High
- SXTP $36.00
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- SXTP 56.45
- GLMD 48.70
- Support Level
- SXTP $2.48
- GLMD $1.30
- Resistance Level
- SXTP $3.45
- GLMD $1.67
- Average True Range (ATR)
- SXTP 0.70
- GLMD 0.14
- MACD
- SXTP 0.02
- GLMD 0.06
- Stochastic Oscillator
- SXTP 47.63
- GLMD 78.77
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.